{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:21:14Z","timestamp":1772706074875,"version":"3.50.1"},"reference-count":77,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004482","name":"Research Sector, Kuwait University","doi-asserted-by":"crossref","award":["YP05\/17"],"award-info":[{"award-number":["YP05\/17"]}],"id":[{"id":"10.13039\/501100004482","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Busulfan (Bu) is an alkylating agent commonly used at high doses in the preparative regimens of hematopoietic stem cell transplantation (HSCT). It has been shown that such high doses of Bu are associated with generalized seizures which are usually managed by prophylactic antiepileptic drugs (AEDs) such as valproic acid (VPA). Being a strong enzyme inhibitor, VPA may inhibit Bu metabolism and thus increase its potential toxicity. Despite its clinical relevance, the potential interaction between Bu and VPA has not yet been evaluated. The aim of the present study was to assess and evaluate the potential drug-drug interaction (DDI) between Bu and VPA. This study was carried out by incubating Bu in laboratory-prepared rat liver-subcellular fractions including S9, microsomes, and cytosol, alone or in combination with VPA. The liver fractions were prepared by differential centrifugation of the liver homogenate. Analysis of Bu was employed using a fully validated LC-MS\/MS method. The validation parameters were within the proposed limits of the international standards guidelines. Bu metabolic stability was assessed by incubating Bu at a concentration of 8 \u03bcg\/ml in liver fractions at 37\u00b0C. There were significant reductions in Bu levels in S9 and cytosolic fractions, whereas these levels were not significantly (P \u02c3 0.05) changed in microsomes. However, in presence of VPA, Bu levels in S9 fraction remained unchanged. These results indicated, for the first time, the potential metabolic interaction of Bu and VPA being in S9 only. This could be explained by inhibiting Bu cytosolic metabolism by the interaction with VPA either by sharing the same metabolic enzyme or the required co-factor. In conclusion, the present findings suggest, for the first time, a potential DDI between Bu and VPA <jats:italic>in vitro<\/jats:italic> using rat liver fractions. Further investigations are warranted in human-derived liver fractions to confirm such an interaction.<\/jats:p>","DOI":"10.1371\/journal.pone.0280574","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T18:36:43Z","timestamp":1674671803000},"page":"e0280574","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction"],"prefix":"10.1371","volume":"18","author":[{"given":"Bashayer F.","family":"Al-Enezi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Al-Hasawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2854-980X","authenticated-orcid":true,"given":"Kamal M.","family":"Matar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"issue":"9","key":"pone.0280574.ref001","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/17425255.2017.1360277","article-title":"Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review","volume":"13","author":"AL Myers","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6753","key":"pone.0280574.ref002","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0140-6736(53)90885-X","article-title":"Myleran in chronic myeloid leukaemia; results of treatment","volume":"264","author":"DA Galton","year":"1953","journal-title":"Lancet"},{"issue":"6","key":"pone.0280574.ref003","first-page":"1781","article-title":"Marrow transplantation in the busulfan-treated rat: preclinical model of aplastic anemia","volume":"53","author":"GW Santos","year":"1974","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"pone.0280574.ref004","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1078155216651128","article-title":"Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients","volume":"23","author":"AE Floeter","year":"2017","journal-title":"J Oncol Pharm Pract"},{"issue":"12","key":"pone.0280574.ref005","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1592\/phco.28.12.1502","article-title":"Optimal prevention of seizures induced by high-dose busulfan","volume":"28","author":"AL Eberly","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"1","key":"pone.0280574.ref006","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2174\/157488608783333899","article-title":"Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children","volume":"3","author":"N Krivoy","year":"2008","journal-title":"Curr Drug Saf"},{"issue":"5","key":"pone.0280574.ref007","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/BF00558081","article-title":"Pharmacokinetic and metabolic studies of high-dose busulphan in adults","volume":"36","author":"M Hassan","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"issue":"16","key":"pone.0280574.ref008","first-page":"3678","article-title":"Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases","volume":"56","author":"JP Gibbs","year":"1996","journal-title":"Cancer Res"},{"issue":"3","key":"pone.0280574.ref009","first-page":"399","article-title":"Urinary metabolites of busulfan in the rat","volume":"15","author":"M Hassan","year":"1987","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"pone.0280574.ref010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0006-2952(59)90052-8","article-title":"Dimethanesulphonoxybutane (Myleran): Preliminary studies on distribution and metabolic fate in the rat","volume":"2","author":"EG Trams","year":"1959","journal-title":"Biochemical Pharmacology"},{"issue":"3","key":"pone.0280574.ref011","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/tpj.2013.38","article-title":"The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation","volume":"14","author":"CR Uppugunduri","year":"2014","journal-title":"Pharmacogenomics J"},{"issue":"11","key":"pone.0280574.ref012","doi-asserted-by":"crossref","first-page":"e0187294","DOI":"10.1371\/journal.pone.0187294","article-title":"Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway","volume":"12","author":"I El-Serafi","year":"2017","journal-title":"PLoS One"},{"key":"pone.0280574.ref013","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jchromb.2012.12.001","article-title":"Gas chromatographic-mass spectrometry method for the detection of busulphan and its metabolites in plasma and urine","volume":"913\u2013914","author":"I El-Serafi","year":"2013","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"5","key":"pone.0280574.ref014","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.bbmt.2008.12.489","article-title":"Busulfan in hematopoietic stem cell transplantation","volume":"15","author":"SO Ciurea","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"pone.0280574.ref015","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.bbmt.2015.05.006","article-title":"Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning","volume":"21","author":"JH Zao","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"pone.0280574.ref016","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.hemonc.2017.03.003","article-title":"Therapeutic drug monitoring-guided dosing of busulfan differs from weight-based dosing in hematopoietic stem cell transplant patients","volume":"10","author":"B Salman","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"2","key":"pone.0280574.ref017","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1188\/06.ONF.E36-E43","article-title":"Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan","volume":"33","author":"VL Fisher","year":"2006","journal-title":"Oncol Nurs Forum"},{"issue":"9","key":"pone.0280574.ref018","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","article-title":"Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia","volume":"8","author":"BS Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"pone.0280574.ref019","author":"JRM Pires","year":"2018","journal-title":"PHARMACOLOGICAL PROFILE AND STRUCTURE- ACTIVITY RELATIONSHIP OF ALKYLATING AGENTS USED IN CANCER TREATMENT"},{"issue":"3","key":"pone.0280574.ref020","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00686213","article-title":"Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics","volume":"33","author":"M Hassan","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"pone.0280574.ref021","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.bbmt.2011.11.029","article-title":"Important drug interactions in hematopoietic stem cell transplantation: what every physician should know","volume":"18","author":"B Glotzbecker","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"pone.0280574.ref022","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00280-018-3659-8","article-title":"Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients","volume":"82","author":"K Akiyama","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"22","key":"pone.0280574.ref023","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2010-01-265405","article-title":"Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring","volume":"115","author":"J Gaziev","year":"2010","journal-title":"Blood"},{"issue":"2","key":"pone.0280574.ref024","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.bbmt.2013.10.028","article-title":"Risk of seizures in children receiving busulphan-containing regimens for stem cell transplantation","volume":"20","author":"D Caselli","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"pone.0280574.ref025","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs","volume":"16","author":"G Zaccara","year":"2014","journal-title":"Epileptic Disord"},{"issue":"5","key":"pone.0280574.ref026","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.0306-5251.2001.01474.x","article-title":"In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)","volume":"52","author":"X Wen","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"pone.0280574.ref027","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/157015910792246254","article-title":"Antiepileptic drug interactions\u2014principles and clinical implications","volume":"8","author":"SI Johannessen","year":"2010","journal-title":"Curr Neuropharmacol"},{"issue":"12","key":"pone.0280574.ref028","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2165\/0003088-200847120-00003","article-title":"The enzymatic basis of drug-drug interactions with systemic triazole antifungals","volume":"47","author":"Y Nivoix","year":"2008","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"pone.0280574.ref029","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1128\/AAC.02931-15","article-title":"Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP","volume":"60","author":"VJ Lempers","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"7\u20138","key":"pone.0280574.ref030","first-page":"e39","article-title":"Busulfan and metronidazole: an often forgotten but significant drug interaction","volume":"45","author":"AM Gulbis","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"4a","key":"pone.0280574.ref031","first-page":"2083","article-title":"Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo)","volume":"16","author":"I Buggia","year":"1996","journal-title":"Anticancer Res"},{"key":"pone.0280574.ref032","volume-title":"Handbook of Drug-nutrient Interactions","author":"VT Armenti","year":"2010"},{"key":"pone.0280574.ref033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4419-0840-7","volume-title":"Enzyme- and transporter-based drug-drug interactions: Progress and future challenges","author":"KS Pang","year":"2010"},{"issue":"1","key":"pone.0280574.ref034","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1038\/s41598-020-65919-9","article-title":"UPLC-Tandem Mass Spectrometry for Quantification of Busulfan in Human Plasma: Application to Therapeutic Drug Monitoring","volume":"10","author":"KM Matar","year":"2020","journal-title":"Sci Rep"},{"key":"pone.0280574.ref035","volume-title":"Drug Administration, FDA Guidance for Industry: Bioanalytical Method Validation, DRAFT GUIDANCE. US Department of Health and Human Services, FDA","author":"US-FDA F","year":"2018"},{"key":"pone.0280574.ref036","first-page":"22","article-title":"Guideline on bioanalytical method validation","author":"EMEA","year":"2011","journal-title":"Committee for Medicinal Products for Human Use"},{"issue":"2","key":"pone.0280574.ref037","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/10408347.2014.980775","article-title":"Biological Matrix Effects in Quantitative Tandem Mass Spectrometry-Based Analytical Methods: Advancing Biomonitoring","volume":"46","author":"P Panuwet","year":"2016","journal-title":"Crit Rev Anal Chem"},{"issue":"1","key":"pone.0280574.ref038","first-page":"54","article-title":"Strategies for the detection and elimination of matrix effects in quantitative LC-MS analysis","volume":"32","author":"AK Hewavitharana","year":"2014","journal-title":"LCGC North America"},{"issue":"1","key":"pone.0280574.ref039","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1570-0232(02)00142-3","article-title":"Ion suppression effects in liquid chromatography-electrospray-ionisation transport-region collision induced dissociation mass spectrometry with different serum extraction methods for systematic toxicological analysis with mass spectra libraries","volume":"773","author":"C M\u00fcller","year":"2002","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"01","key":"pone.0280574.ref040","first-page":"9","volume":"06","author":"ES AlGamdi","year":"2017","journal-title":"Effect of Avocado on Serum Lipids of Hyperlipidemic Rats Current Science International"},{"issue":"7","key":"pone.0280574.ref041","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.tiv.2012.06.011","article-title":"Screening of the inhibitory effect of xenobiotics on alcohol metabolism using S9 rat liver fractions","volume":"26","author":"C Dias","year":"2012","journal-title":"Toxicol In Vitro"},{"issue":"38","key":"pone.0280574.ref042","doi-asserted-by":"crossref","DOI":"10.3791\/1918-v","article-title":"Linearization of the bradford protein assay","author":"O Ernst","year":"2010","journal-title":"J Vis Exp"},{"key":"pone.0280574.ref043","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"MM Bradford","year":"1976","journal-title":"Anal Biochem"},{"issue":"3","key":"pone.0280574.ref044","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3390\/s90302134","article-title":"EROD and MROD as Markers of Cytochrome P450 1A Activities in Hepatic Microsomes from Entire and Castrated Male Pigs","volume":"9","author":"G Zamaratskaia","year":"2009","journal-title":"Sensors (Basel)"},{"issue":"2","key":"pone.0280574.ref045","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0378-4347(00)00278-4","article-title":"Determination of cytochrome P450 1A activities in mammalian liver microsomes by high-performance liquid chromatography with fluorescence detection","volume":"744","author":"N Hanioka","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl"},{"issue":"2","key":"pone.0280574.ref046","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/1872312810666160223121836","article-title":"Efficiency in Drug Discovery: Liver S9 Fraction Assay As a Screen for Metabolic Stability.","volume":"10","author":"SJ Richardson","year":"2016","journal-title":"Drug Metab Lett"},{"issue":"2","key":"pone.0280574.ref047","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/138920012798918426","article-title":"Liver-based in vitro technologies for drug biotransformation studies\u2014a review","volume":"13","author":"P Fasinu","year":"2012","journal-title":"Curr Drug Metab"},{"issue":"13","key":"pone.0280574.ref048","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"BK Matuszewski","year":"2003","journal-title":"Anal Chem"},{"key":"pone.0280574.ref049","volume-title":"Tandem Mass Spectrometry","author":"GH Terence","year":"2012"},{"issue":"12","key":"pone.0280574.ref050","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1023\/A:1007669411738","article-title":"Bioanalytical method validation\u2014a revisit with a decade of progress","volume":"17","author":"VP Shah","year":"2000","journal-title":"Pharm Res"},{"issue":"3","key":"pone.0280574.ref051","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1208\/s12248-014-9573-z","article-title":"Stability: recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Team","volume":"16","author":"N van de Merbel","year":"2014","journal-title":"Aaps j"},{"issue":"3","key":"pone.0280574.ref052","doi-asserted-by":"crossref","first-page":"E353","DOI":"10.1208\/aapsj0903042","article-title":"Determination of carryover and contamination for mass spectrometry-based chromatographic assays","volume":"9","author":"NC Hughes","year":"2007","journal-title":"Aaps j"},{"issue":"1","key":"pone.0280574.ref053","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/0006-291X(85)91687-0","article-title":"Glutathione S-transferases catalyzed conjugation of 1,4-disubstituted butanes with glutathione in vitro","volume":"128","author":"DH Marchand","year":"1985","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"pone.0280574.ref054","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective","volume":"31","author":"TD Bjornsson","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"pone.0280574.ref055","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2174\/138920007782798207","article-title":"The conduct of drug metabolism studies considered good practice (II): in vitro experiments","volume":"8","author":"L Jia","year":"2007","journal-title":"Curr Drug Metab"},{"issue":"3","key":"pone.0280574.ref056","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41409-018-0281-7","article-title":"Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children","volume":"54","author":"M Philippe","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"pone.0280574.ref057","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bbmt.2006.08.037","article-title":"Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule","volume":"13","author":"T Madden","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"pone.0280574.ref058","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1124\/dmd.110.033894","article-title":"Effect of regular organic solvents on cytochrome P450-mediated metabolic activities in rat liver microsomes","volume":"38","author":"D Li","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"pone.0280574.ref059","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.32.4.413","article-title":"Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid","volume":"32","author":"V Uchaipichat","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"pone.0280574.ref060","first-page":"141","article-title":"Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes","volume":"29","author":"J Easterbrook","year":"2001","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"pone.0280574.ref061","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1248\/bpb.b17-00654","article-title":"Pharmacokinetics and Metabolism of Streptochlorin and Its Synthetic Derivative, 5-Hydroxy-2\u2019-isobutyl Streptochlorin, in Mice","volume":"41","author":"Y Zhou","year":"2018","journal-title":"Biol Pharm Bull"},{"key":"pone.0280574.ref062","article-title":"Assessment of metabolic stability using the rainbow trout (Oncorhynchus mykiss) liver S9 fraction","author":"K Johanning","year":"2012","journal-title":"Curr Protoc Toxicol"},{"issue":"4","key":"pone.0280574.ref063","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/dmd.104.003004","article-title":"Human liver S9 fractions: metabolism of dehydroepiandrosterone, epiandrosterone, and related 7-hydroxylated derivatives","volume":"33","author":"S Chalbot","year":"2005","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"pone.0280574.ref064","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1006\/taap.2002.9440","article-title":"Drug metabolites in safety testing","volume":"182","author":"TA Baillie","year":"2002","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"pone.0280574.ref065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1124\/dmd.118.082099","article-title":"Evaluation of Carbazeran 4-Oxidation and O (6)-Benzylguanine 8-Oxidation as Catalytic Markers of Human Aldehyde Oxidase: Impact of Cytosolic Contamination of Liver Microsomes","volume":"47","author":"J Xie","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"pone.0280574.ref066","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fphar.2019.00234","article-title":"Application of in vitro Drug Metabolism Studies in Chemical Structure Optimization for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)","volume":"10","author":"EC Padilha","year":"2019","journal-title":"Front Pharmacol"},{"key":"pone.0280574.ref067","author":"IR Younis","year":"2008","journal-title":"In vitro elucidation of the metabolic fate of the anticancer drug busulfan"},{"issue":"3","key":"pone.0280574.ref068","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1124\/jpet.108.142208","article-title":"Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1","volume":"327","author":"IR Younis","year":"2008","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"pone.0280574.ref069","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0378-4347(99)00170-X","article-title":"Determination of tetrahydrothiophene formation as a probe of in vitro busulfan metabolism by human glutathione S-transferase A1-1: use of a highly sensitive gas chromatographic-mass spectrometric method","volume":"730","author":"CA Ritter","year":"1999","journal-title":"J Chromatogr B Biomed Sci Appl"},{"issue":"1","key":"pone.0280574.ref070","first-page":"52","article-title":"Comparison of human liver and small intestinal glutathione S-transferase-catalyzed busulfan conjugation in vitro","volume":"26","author":"JP Gibbs","year":"1998","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"pone.0280574.ref071","first-page":"1015","article-title":"Busulfan conjugation by glutathione S-transferases alpha, mu, and pi","volume":"24","author":"M Czerwinski","year":"1996","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"pone.0280574.ref072","first-page":"436","article-title":"Conjugation of glutathione with a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, catalyzed by rat hepatic glutathione-S-transferases","volume":"24","author":"W Tang","year":"1996","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"pone.0280574.ref073","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.","volume":"16","author":"W. L\u00f6scher","year":"2002","journal-title":"CNS Drugs"},{"issue":"6","key":"pone.0280574.ref074","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1600-0773.1999.tb02025.x","article-title":"Effect of acute and chronic administration of sodium valproate on lipid peroxidation and antioxidant system in rat liver","volume":"85","author":"S Se\u00e7kin","year":"1999","journal-title":"Pharmacol Toxicol"},{"issue":"3","key":"pone.0280574.ref075","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0006-2952(90)90560-8","article-title":"Early changes in hepatic redox homeostasis following treatment with a single dose of valproic acid","volume":"40","author":"D Cotariu","year":"1990","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"pone.0280574.ref076","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0300-483X(96)03352-5","article-title":"Cytotoxicity of unsaturated metabolites of valproic acid and protection by vitamins C and E in glutathione-depleted rat hepatocytes","volume":"112","author":"M Jurima-Romet","year":"1996","journal-title":"Toxicology"},{"issue":"6","key":"pone.0280574.ref077","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.bmt.1703896","article-title":"The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation","volume":"31","author":"C Nilsson","year":"2003","journal-title":"Bone Marrow Transplant"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0280574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T18:37:23Z","timestamp":1674671843000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0280574"}},"subtitle":[],"editor":[{"given":"Vinod Kumar","family":"Vashistha","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0280574","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]}}}